BioCentury
ARTICLE | Clinical News

AP301: Phase IIa start

April 29, 2013 7:00 AM UTC

Next month, Apeptico will begin a placebo-controlled, Austrian Phase IIa trial to evaluate AP301 delivered via aerosol by nebulizer technology for up to 7 days in mechanically ventilated patients with...